ARX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 26.99%

Insider Buying (Last 12 Months): A$224,950.00

Insider Selling (Last 12 Months): A$0.00

Aroa Biosurgery Insider Trading History Chart

Aroa Biosurgery Share Price & Price History

A^$0.00

+0.30 (1.20%)

As of 06/28/2019 01:00 AM ET

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Aroa Biosurgery Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/27/2024	Steven (Steve) Engle	Insider	Issued	633,225	A$0.10	A$62,056.05
2/16/2024	Philip McCaw	Insider	Buy	326,000	A$0.58	A$187,450.00
9/6/2023	James (Jim) McLean	Insider	Buy	50,000	A$0.75	A$37,500.00
8/11/2023	Catherine Mohr	Insider	Issued	210,686	A$0.88	A$185,403.68
3/31/2023	Philip McCaw	Insider	Issued	172,620	A$1.05	A$181,251.00
12/14/2022	John Diddams	Insider	Exercise	165,000	A$0.11	A$17,655.00
4/12/2022	Philip McCaw	Insider	Exercise	81,925	A$0.75	A$61,443.75
3/25/2022	John Diddams	Insider	Buy	165,000	A$0.11	A$17,655.00
8/19/2021	James (Jim) McLean	Insider	Exercise	102,400	A$0.75	A$76,800.00
8/6/2021	Philip McCaw	Insider	Transfer	2,864,879	A$1.15	A$3,297,475.73
6/11/2021	Philip McCaw	Insider	Buy	81,925	A$0.75	A$61,443.75

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad

This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

SEC Filings (Institutional Ownership Changes) for Aroa Biosurgery (ASX:ARX)

13.33% of Aroa Biosurgery stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and sells medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. The company was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Who are the company insiders with the largest holdings of Aroa Biosurgery?: Aroa Biosurgery's top insider shareholders include:
Catherine Mohr (Insider)
James (Jim) McLean (Insider)
John Diddams (Insider)
Philip McCaw (Insider)
Steven (Steve) Engle (Insider)
Learn More about top insider investors at Aroa Biosurgery.